Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Mary Imogene Bassett Hospital — Cooperstown, New York
- The Cancer Institute at Saint Francis Hospital — East Hills, New York
- Arnot Ogden Medical Center/Falck Cancer Center — Elmira, New York
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Montefiore Medical Center-Einstein Campus — The Bronx, New York
- Montefiore Medical Center-Weiler Hospital — The Bronx, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
- James J Peters VA Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in New York: - New York Oncology Hematology — Albany, New York
- New York Oncology Hematology — Clifton Park, New York
- Hematology Oncology Associates of Rockland — Nyack, New York
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of CNY at Camillus — Camillus, New York
- Hematology Oncology Associates of Central New York-East Syracuse — East Syracuse, New York
- Stony Brook University Medical Center — Stony Brook, New York
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in New York: - Maimonides Cancer Center — Brooklyn, New York
- Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center — New York, New York
- Manhattan Eye, Ear and Throat Hospital — New York, New York
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in New York: - Research Site — Buffalo, New York
- Research Site — East Syracuse, New York
- Research Site — Westbury, New York
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in New York: - Northwell Health/Center for Advanced Medicine — Lake Success, New York
- Mount Sinai Chelsea — New York, New York
- Mount Sinai West — New York, New York
- Mount Sinai Hospital — New York, New York
- Manhattan Eye Ear and Throat Hospital — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in New York: - Local Institution - 0356 — Hawthorne, New York
- Veterans Affairs New York Harbor Healthcare System — New York, New York
- Local Institution - 0380 — Northport, New York
- University of Rochester Medical Center — Rochester, New York
- Local Institution - 0511 — Schenectady, New York
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in New York: - Roswell Park Cancer Institute ( Site 0184) — Buffalo, New York
- Hematology-Oncology Associates of CNY ( Site 0164) — East Syracuse, New York
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216) — New York, New York
- Icahn School of Medicine at Mount Sinai ( Site 0116) — New York, New York
- Memorial Sloan Kettering Cancer Center ( Site 0137) — New York, New York
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in New York: - Nuvance Health — Poughkeepsie, New York
- Suny-Stony Brook University Cancer Center — Stony Brook, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Sites in New York: - Maimonides Medical Center /ID# 240783 — Brooklyn, New York
- Northwell Health - Monter Cancer Center /ID# 247081 — Lake Success, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in New York: - Local Institution - 0224 — Laurelton, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Optum Medical Care, PC — Westbury, New York
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in New York: - Research Site — Buffalo, New York
- Research Site — East Syracuse, New York
- Research Site — Fresh Meadows, New York
- Research Site — Rochester, New York
- Research Site — Westbury, New York
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in New York: - New York Cancer & Blood Specialists (NYCBS) — New Hyde Park, New York
- New York Cancer & Blood Specialists (NYCBS) — New York, New York
- University of Rochester Medical Center — Rochester, New York
- New York Cancer & Blood Specialists (NYCBS) — Shirley, New York
- New York Cancer & Blood Specialists (NYCBS) — The Bronx, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT07128199
Sites in New York: - Memorial Sloan Kettering Cancer Center - Commack — Commack, New York
- Memorial Sloan Kettering Cancer Center - Westchester — East White Plains, New York
- Long Island Jewish Medical Center — Lake Success, New York
- Perlmutter Cancer Center - 34th Street — New York, New York
- Memorial Sloan Kettering Cancer Center - New York — New York, New York
Phase 2, Phase 3 Recruiting Industry
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Sponsor: Eikon Therapeutics
NCT ID: NCT07365319
Sites in New York: - NYU Langone Hospital Long Island — Mineola, New York
- NYU Langone Hospital Manhattan — New York, New York
- Jacobi Medical Center - Albert Einstein College of Medicine — The Bronx, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07410117
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aim…
Sponsor: GlaxoSmithKline
NCT ID: NCT07099898
Sites in New York: - GSK Investigational Site — East Syracuse, New York
Phase 3 Recruiting Industry
This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene b…
Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07660094
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in New York: - Arnot Ogden Medical Center/Falck Cancer Center — Elmira, New York
- University of Rochester — Rochester, New York
- Montefiore Medical Center-Einstein Campus — The Bronx, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
- James J Peters VA Medical Center — The Bronx, New York
Phase 2 Recruiting NIH
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03191149
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Garnet Health Medical Center — Middletown, New York
- Dickstein Cancer Treatment Center — White Plains, New York
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- New York Proton Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Upstate Cancer Center at Oswego — Oswego, New York
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…
Sponsor: Synthekine
NCT ID: NCT05098132
Sites in New York: - Northwell Health — Lake Success, New York
- NYU Langone Health — New York, New York
- Columbia University Irving Medical Center — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
Phase 2 Recruiting Industry
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…
Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in New York: - Roswell Park Center Institute — Buffalo, New York
- NYU Langone Health — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in New York: - Research Site 107 — New York, New York